Estracure

EstraCure is a Swedish clinical-stage biotechnology company focused on developing innovative treatments for advanced prostate cancer. The company's primary focus is on its lead candidate, EC-102, a targeted estrogen therapy designed to treat castration-resistant prostate cancer (CRPC). EC-102 aims to deliver the anti-tumor effects of estrogen directly to the prostate while avoiding the systemic side effects typically associated with estrogen treatments, such as cardiovascular issues and feminization. Founded by researchers from Umeå University, EstraCure leverages deep expertise in prostate cancer biology and endocrine signaling. The company operates out of the Umeå Biotech Incubator and seeks to address the significant unmet need in patients who no longer respond to conventional androgen-deprivation therapies.